Target- |
MechanismStem cell replacements |
|
|
|
|
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Undifferentiated human fetal brain-derived stem cells grafted into putamina of parkinsonian patients is safe and moderately effective: a phase I clinical trial.
100 Clinical Results associated with Celavie Biosciences LLC
0 Patents (Medical) associated with Celavie Biosciences LLC
100 Deals associated with Celavie Biosciences LLC
100 Translational Medicine associated with Celavie Biosciences LLC